Welcome to our dedicated page for Candel Therapeutics SEC filings (Ticker: CADL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Candel Therapeutics, Inc. filings document a clinical-stage oncology company developing multimodal biological immunotherapies and reporting as a Nasdaq-listed issuer of common stock. Its proxy materials cover director elections, auditor ratification and annual-meeting voting matters, while Form 8-K reports furnish operating and financial results and research-and-development presentations.
Other filings disclose material agreements and capital-structure matters, including term-loan financing and facility lease amendments, along with clinical and regulatory disclosures tied to aglatimagene besadenovec and linoserpaturev. The filing record also reflects governance matters, shareholder voting mechanics and exhibit-based disclosures for key corporate actions.
BlackRock, Inc. reported a passive ownership position in Candel Therapeutics, Inc. common stock on a Schedule 13G. BlackRock disclosed beneficial ownership of 4,834,899 shares of common stock, representing 6.6% of Candel Therapeutics’ outstanding common shares.
BlackRock reported sole voting power over 4,763,922 shares and sole dispositive power over 4,834,899 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of Candel’s outstanding common shares.
Candel Therapeutics Chief Commercial Officer Mark E. Sims received a grant of stock options covering 285,000 shares of common stock. The options have an exercise price of $10.03 per share and expire on July 6, 2036. Twenty-five percent vest on July 6, 2027, with the remainder vesting in 36 equal monthly installments, contingent on continued service.
Candel Therapeutics, Inc. filed a Form 3 identifying Mark E. Sims as an officer of the company, serving as Chief Commercial Officer. The filing does not report any share transactions or holdings for Sims, and the transaction summary shows no purchases, sales, exercises, gifts, or other movements.
Candel Therapeutics Chief Scientific Officer Francesca Barone sold 23,447 shares of common stock in an open-market transaction at a weighted average price of $10.0554 per share on June 29, 2026. The sale was executed under a Rule 10b5-1 trading plan adopted on March 16, 2026, and Barone now directly holds 77,362 shares.
Candel Therapeutics, Inc. Chief Technology Officer Tyagarajan Seshu reported an open-market sale of 7,000 shares of common stock at a weighted average price of $10.0216 per share on June 29, 2026. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 16, 2026.
After this transaction, Seshu directly holds 83,865 shares of Candel Therapeutics common stock. The price reflected a range of individual trades between $10.00 and $10.07 per share.
Candel Therapeutics director Paul B. Manning received a grant of stock options as compensation. He was awarded options to buy 2,199 shares of common stock at an exercise price of $10.30 per share. The award replaces normal quarterly cash payments and is fully vested at the time of grant, leaving him with 2,199 derivative securities after this transaction.
Candel Therapeutics director Joseph C. Papa received a new stock option award as part of his board compensation. The grant covers 1,331 options to buy common stock at an exercise price of $10.30 per share.
The award was granted in lieu of normal quarterly cash payments and is fully vested at the time of grant, so Papa can exercise all 1,331 options any time until their expiration if he chooses.
Candel Therapeutics director Nicoletta Loggia received a grant of stock options as compensation. The award covers 381 options to buy Candel common stock at an exercise price of $10.30 per share, expiring on June 30, 2036. According to the disclosure, this award was granted in lieu of normal quarterly cash payments and is fully vested at the time of grant. Following the grant, Loggia holds 381 stock options directly.